Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1855–1859. doi: 10.1128/aac.40.8.1855

Trovafloxacin is active against Toxoplasma gondii.

A A Khan 1, T Slifer 1, F G Araujo 1, J S Remington 1
PMCID: PMC163429  PMID: 8843293

Abstract

Drugs currently used for treatment of toxoplasmosis in pregnant women, congenital infections, immunocompromised patients, and patients with the ocular disease are not always effective or may be dangerous to use; therefore, there is a need for more-effective and less-toxic drugs. Recently, we examined a group of fluoroquinolones for in vitro and in vivo activities against Toxoplasma gondii. Among those examined in vitro (ciprofloxacin, fleroxacin, ofloxacin, temafloxacin, and trovafloxacin), only trovafloxacin significantly inhibited intracellular replication of T. gondii without significant toxicity for host cells. In a murine model of acute toxoplasmosis, 100 or 200 mg of trovafloxacin per kg of body weight per day for 10 days protected 100% of infected mice against death. A dose of 50 mg/kg/day protected 90% of the mice, and a dose of 25 mg/kg/day effected prolongation of time to death. The other fluoroquinolones did not have such in vivo activities. These results indicate that trovafloxacin may be useful for treatment of toxoplasmosis in humans.

Full Text

The Full Text of this article is available as a PDF (197.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Huskinson J., Remington J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991 Feb;35(2):293–299. doi: 10.1128/aac.35.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Araujo F. G., Remington J. S. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother. 1974 Jun;5(6):647–651. doi: 10.1128/aac.5.6.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. COOK M. K., JACOBS L. In vitro investigations on the action of pyrimethamine against Toxoplasma gondii. J Parasitol. 1958 Jun;44(3):280–288. [PubMed] [Google Scholar]
  5. Carbone L. G., Bendixen B., Appel G. B. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis. 1988 Jul;12(1):72–75. doi: 10.1016/s0272-6386(88)80076-3. [DOI] [PubMed] [Google Scholar]
  6. Cohn J. A., McMeeking A., Cohen W., Jacobs J., Holzman R. S. Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med. 1989 May;86(5):521–527. doi: 10.1016/0002-9343(89)90378-1. [DOI] [PubMed] [Google Scholar]
  7. Dannemann B. R., Morris V. A., Araujo F. G., Remington J. S. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts. J Immunol. 1989 Oct 15;143(8):2684–2691. [PubMed] [Google Scholar]
  8. Derouin F., Sarfati C., Beauvais B., Garin Y. J., Larivière M. Prevalence of pulmonary toxoplasmosis in HIV-infected patients. AIDS. 1990 Oct;4(10):1036–1036. [PubMed] [Google Scholar]
  9. Espinoza A. M., Chin N. X., Novelli A., Neu H. C. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988 May;32(5):663–670. doi: 10.1128/aac.32.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fujimaki K., Noumi T., Saikawa I., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827–833. doi: 10.1128/aac.32.6.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gooding B. B., Jones R. N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993 Feb;37(2):349–353. doi: 10.1128/aac.37.2.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  13. Israelski D. M., Remington J. S. Toxoplasmic encephalitis in patients with AIDS. Infect Dis Clin North Am. 1988 Jun;2(2):429–445. [PubMed] [Google Scholar]
  14. Maxwell A. The molecular basis of quinolone action. J Antimicrob Chemother. 1992 Oct;30(4):409–414. doi: 10.1093/jac/30.4.409. [DOI] [PubMed] [Google Scholar]
  15. Mitsuyama J., Itoh Y., Takahata M., Okamoto S., Yasuda T. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Antimicrob Agents Chemother. 1992 Sep;36(9):2030–2036. doi: 10.1128/aac.36.9.2030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Noumi T., Nishida N., Minami S., Watanabe Y., Yasuda T. Intracellular activity of tosufloxacin (T-3262) against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin. Antimicrob Agents Chemother. 1990 Jun;34(6):949–953. doi: 10.1128/aac.34.6.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Oksenhendler E., Cadranel J., Sarfati C., Katlama C., Datry A., Marche C., Wolf M., Roux P., Derouin F., Clauvel J. P. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am J Med. 1990 May;88(5N):18N–21N. [PubMed] [Google Scholar]
  18. Pomeroy C., Filice G. A. Pulmonary toxoplasmosis: a review. Clin Infect Dis. 1992 Apr;14(4):863–870. doi: 10.1093/clinids/14.4.863. [DOI] [PubMed] [Google Scholar]
  19. Sahai J., Heimberger T., Collins K., Kaplowitz L., Polk R. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med. 1988 Apr;84(4):791–792. doi: 10.1016/0002-9343(88)90124-6. [DOI] [PubMed] [Google Scholar]
  20. Sutcliffe J. A., Gootz T. D., Barrett J. F. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob Agents Chemother. 1989 Dec;33(12):2027–2033. doi: 10.1128/aac.33.12.2027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Teng R., Harris S. C., Nix D. E., Schentag J. J., Foulds G., Liston T. E. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995 Aug;36(2):385–394. doi: 10.1093/jac/36.2.385. [DOI] [PubMed] [Google Scholar]
  22. Torroba Alvarez L., Hermida Donate J. M., Ezpeleta Baquedano C., Muñoz Zato E. Metahemoglobinemia secundaria al tratamiento de infecciones oportunistas en pacientes con SIDA. Rev Clin Esp. 1988 Mar;182(5):289–290. [PubMed] [Google Scholar]
  23. Wise R., Mortiboy D., Child J., Andrews J. M. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother. 1996 Jan;40(1):47–49. doi: 10.1128/aac.40.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zimmer C., Störl K., Störl J. Microbial DNA topoisomerases and their inhibition by antibiotics. J Basic Microbiol. 1990;30(3):209–224. doi: 10.1002/jobm.3620300312. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES